MED19
Mediator of RNA polymerase II transcription subunit 19
Also known as: LCMR1, MED19_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- A0JLT2
- Gene
- MED19
- Ensembl
- ENSG00000156603
- Chromosome
- 11
- Canonical length
- 244 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nuclear bodies
OverviewNCBI Gene
The protein encoded by this gene is a subunit of the Mediator complex, which binds to gene-specific regulatory factors and provides support for the basal RNA polymerase II transcription machinery. This gene has been implicated in the growth of several types of cancer, and inhibition of its expression inhibits the growth and spread of these cancers. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2015]
Canonical amino-acid sequenceUniProt
244 residues, UniProt reviewed canonical sequence.
>A0JLT2|MED19
1 MENFTALFGA QADPPPPPTA LGFGPGKPPP PPPPPAGGGP GTAPPPTAAT APPGADKSGA
61 GCGPFYLMRE LPGSTELTGS TNLITHYNLE QAYNKFCGKK VKEKLSNFLP DLPGMIDLPG
121 SHDNSSLRSL IEKPPILSSS FNPITGTMLA GFRLHTGPLP EQCRLMHIQP PKKKNKHKHK
181 QSRTQDPVPP ETPSDSDHKK KKKKKEEDPD RKRKKKEKKK KKNRHSPDHP GMGSSQASSS
241 SSLRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MED19 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.66
- Highest tissue expression
- 24 nTPM
Expression across tissuesHPA
Tissue
- choroid plexus: 24 nTPM
- testis: 24 nTPM
- cerebral cortex: 20 nTPM
- adrenal gland: 18 nTPM
- basal ganglia: 18 nTPM
- pituitary gland: 17 nTPM
Single-cell type
- oocytes: 193 nCPM
- esophageal apical cells: 98 nCPM
- early primary spermatocytes: 95 nCPM
- late primary spermatocytes: 93 nCPM
- undifferentiated spermatogonia: 90 nCPM
- differentiating spermatogonia: 90 nCPM
Immune cell
- memory B-cell: 50 nTPM
- naive B-cell: 44 nTPM
- non-classical monocyte: 44 nTPM
- intermediate monocyte: 41 nTPM
- plasmacytoid DC: 41 nTPM
- naive CD4 T-cell: 38 nTPM
Brain region
- thalamus: 25 nTPM
- cerebral cortex: 23 nTPM
- basal ganglia: 19 nTPM
- white matter: 18 nTPM
- midbrain: 18 nTPM
- amygdala: 17 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.59
- gnomAD pLI
- 0.78
- gnomAD missense Z
- 0.77
- DepMap mean gene effect
- -0.49
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- positive regulation of transcription by RNA polymerase II
- positive regulation of transcription elongation by RNA polymerase II
- positive regulation of transcription initiation by RNA polymerase II
- RNA polymerase II preinitiation complex assembly
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Mediator complex, subunit Med19, metazoa
- Mediator of RNA pol II transcription subunit 19
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MED19 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MED19 as an antibody target. Whether an autoantibody or antibody against MED19 could matter depends on whether native MED19 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MED19 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MED19 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...